Cargando…
HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation
Rabbit anti-thymocyte globulins (ATGs) are widely used for the prevention of acute and chronic graft versus host disease (aGVHD, cGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). However, most prospective and retrospective studies did not reveal an overall survival (OS) ben...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489799/ https://www.ncbi.nlm.nih.gov/pubmed/28536356 http://dx.doi.org/10.3390/biomedicines5020013 |
_version_ | 1783246862363394048 |
---|---|
author | Clausen, Johannes Böhm, Alexandra Straßl, Irene Stiefel, Olga Buxhofer-Ausch, Veronika Machherndl-Spandl, Sigrid König, Josef Schmidt, Stefan Steitzer, Hansjörg Danzer, Martin Kasparu, Hedwig Weltermann, Ansgar Nachbaur, David |
author_facet | Clausen, Johannes Böhm, Alexandra Straßl, Irene Stiefel, Olga Buxhofer-Ausch, Veronika Machherndl-Spandl, Sigrid König, Josef Schmidt, Stefan Steitzer, Hansjörg Danzer, Martin Kasparu, Hedwig Weltermann, Ansgar Nachbaur, David |
author_sort | Clausen, Johannes |
collection | PubMed |
description | Rabbit anti-thymocyte globulins (ATGs) are widely used for the prevention of acute and chronic graft versus host disease (aGVHD, cGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). However, most prospective and retrospective studies did not reveal an overall survival (OS) benefit associated with ATG. Homozygosity for human leukocyte antigen (HLA)-C group 1 killer-cell immunoglobulin-like receptor ligands (KIR-L), i.e. C1/1 KIR-L status, was recently shown to be a risk factor for severe aGVHD. Congruously, we have previously reported favorable outcomes in C1/1 recipients after ATG-based transplants in a monocentric analysis. Here, within an extended cohort, we test the hypothesis that incorporation of ATG for GVHD prophylaxis may improve survival particularly in HSCT recipients with at least one C1 KIR-ligand. Retrospectively, 775 consecutive allogeneic (excluding haploidentical) HSCTs were analyzed, including peripheral blood and bone marrow grafts for adults with hematological diseases at two Austrian HSCT centers. ATG-Fresenius/Grafalon, Thymoglobuline, and alemtuzumab were applied in 256, 87, and 7 transplants, respectively (subsequently summarized as “ATG”), while 425 HSCT were performed without ATG. Median follow-up of surviving patients is 48 months. Adjusted for age, disease-risk, HLA-match, donor and graft type, sex match, cytomegalovirus serostatus, conditioning intensity, and type of post-grafting GVHD prophylaxis, Cox regression analysis of the entire cohort (n = 775) revealed a significant association of ATG with decreased non-relapse mortality (NRM) (risk ratio (RR), 0.57; p = 0.001), and overall mortality (RR, 0.71; p = 0.014). Upon stratification for HLA-C KIR-L, the greatest benefit for ATG emerged in C1/1 recipients (n = 291), by reduction of non-relapse (RR, 0.34; p = 0.0002) and overall mortality (RR, 0.50; p = 0.003). Less pronounced, ATG decreased NRM (RR, 0.60; p = 0.036) in HLA-C group 1/2 recipients (n = 364), without significantly influencing overall mortality (RR, 0.70; p = 0.065). After exclusion of higher-dose ATG-based transplants, serotherapy significantly improved both NRM (RR, 0.54; p = 0.019; n = 322) and overall mortality (RR, 0.60; p = 0.018) in C1/2 recipients as well. In both, C1/1 (RR, 1.70; p = 0.10) and particularly in C1/2 recipients (RR, 0.94; p = 0.81), there was no statistically significant impact of ATG on relapse incidence. By contrast, in C2/2 recipients (n = 121), ATG neither reduced NRM (RR, 1.10; p = 0.82) nor overall mortality (RR, 1.50; p = 0.17), but increased the risk for relapse (RR, 4.38; p = 0.02). These retrospective findings suggest ATG may provide a survival benefit in recipients with at least one C1 group KIR-L, by reducing NRM without significantly increasing the relapse risk. |
format | Online Article Text |
id | pubmed-5489799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54897992017-06-30 HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation Clausen, Johannes Böhm, Alexandra Straßl, Irene Stiefel, Olga Buxhofer-Ausch, Veronika Machherndl-Spandl, Sigrid König, Josef Schmidt, Stefan Steitzer, Hansjörg Danzer, Martin Kasparu, Hedwig Weltermann, Ansgar Nachbaur, David Biomedicines Article Rabbit anti-thymocyte globulins (ATGs) are widely used for the prevention of acute and chronic graft versus host disease (aGVHD, cGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). However, most prospective and retrospective studies did not reveal an overall survival (OS) benefit associated with ATG. Homozygosity for human leukocyte antigen (HLA)-C group 1 killer-cell immunoglobulin-like receptor ligands (KIR-L), i.e. C1/1 KIR-L status, was recently shown to be a risk factor for severe aGVHD. Congruously, we have previously reported favorable outcomes in C1/1 recipients after ATG-based transplants in a monocentric analysis. Here, within an extended cohort, we test the hypothesis that incorporation of ATG for GVHD prophylaxis may improve survival particularly in HSCT recipients with at least one C1 KIR-ligand. Retrospectively, 775 consecutive allogeneic (excluding haploidentical) HSCTs were analyzed, including peripheral blood and bone marrow grafts for adults with hematological diseases at two Austrian HSCT centers. ATG-Fresenius/Grafalon, Thymoglobuline, and alemtuzumab were applied in 256, 87, and 7 transplants, respectively (subsequently summarized as “ATG”), while 425 HSCT were performed without ATG. Median follow-up of surviving patients is 48 months. Adjusted for age, disease-risk, HLA-match, donor and graft type, sex match, cytomegalovirus serostatus, conditioning intensity, and type of post-grafting GVHD prophylaxis, Cox regression analysis of the entire cohort (n = 775) revealed a significant association of ATG with decreased non-relapse mortality (NRM) (risk ratio (RR), 0.57; p = 0.001), and overall mortality (RR, 0.71; p = 0.014). Upon stratification for HLA-C KIR-L, the greatest benefit for ATG emerged in C1/1 recipients (n = 291), by reduction of non-relapse (RR, 0.34; p = 0.0002) and overall mortality (RR, 0.50; p = 0.003). Less pronounced, ATG decreased NRM (RR, 0.60; p = 0.036) in HLA-C group 1/2 recipients (n = 364), without significantly influencing overall mortality (RR, 0.70; p = 0.065). After exclusion of higher-dose ATG-based transplants, serotherapy significantly improved both NRM (RR, 0.54; p = 0.019; n = 322) and overall mortality (RR, 0.60; p = 0.018) in C1/2 recipients as well. In both, C1/1 (RR, 1.70; p = 0.10) and particularly in C1/2 recipients (RR, 0.94; p = 0.81), there was no statistically significant impact of ATG on relapse incidence. By contrast, in C2/2 recipients (n = 121), ATG neither reduced NRM (RR, 1.10; p = 0.82) nor overall mortality (RR, 1.50; p = 0.17), but increased the risk for relapse (RR, 4.38; p = 0.02). These retrospective findings suggest ATG may provide a survival benefit in recipients with at least one C1 group KIR-L, by reducing NRM without significantly increasing the relapse risk. MDPI 2017-03-28 /pmc/articles/PMC5489799/ /pubmed/28536356 http://dx.doi.org/10.3390/biomedicines5020013 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Clausen, Johannes Böhm, Alexandra Straßl, Irene Stiefel, Olga Buxhofer-Ausch, Veronika Machherndl-Spandl, Sigrid König, Josef Schmidt, Stefan Steitzer, Hansjörg Danzer, Martin Kasparu, Hedwig Weltermann, Ansgar Nachbaur, David HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation |
title | HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation |
title_full | HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation |
title_fullStr | HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation |
title_full_unstemmed | HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation |
title_short | HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation |
title_sort | hla-c kir-ligands determine the impact of anti-thymocyte globulin (atg) on graft versus host and graft versus leukemia effects following hematopoietic stem cell transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489799/ https://www.ncbi.nlm.nih.gov/pubmed/28536356 http://dx.doi.org/10.3390/biomedicines5020013 |
work_keys_str_mv | AT clausenjohannes hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT bohmalexandra hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT straßlirene hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT stiefelolga hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT buxhoferauschveronika hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT machherndlspandlsigrid hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT konigjosef hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT schmidtstefan hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT steitzerhansjorg hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT danzermartin hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT kasparuhedwig hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT weltermannansgar hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation AT nachbaurdavid hlackirligandsdeterminetheimpactofantithymocyteglobulinatgongraftversushostandgraftversusleukemiaeffectsfollowinghematopoieticstemcelltransplantation |